Your browser doesn't support javascript.
loading
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
Hovingh, G Kees; Lepor, Norman E; Kallend, David; Stoekenbroek, Robert M; Wijngaard, Peter L J; Raal, Frederick J.
Affiliation
  • Hovingh GK; Department of Internal Medicine, Amsterdam UMC, The Netherlands (G.K.H.).
  • Lepor NE; Geffen School of Medicine, University of California, Los Angeles (N.E.L.).
  • Kallend D; Cardiovascular, The Medicines Company, Parsippany, NJ (D.K., R.M.S., P.L.J.W.).
  • Stoekenbroek RM; Cardiovascular, The Medicines Company, Parsippany, NJ (D.K., R.M.S., P.L.J.W.).
  • Wijngaard PLJ; Cardiovascular, The Medicines Company, Parsippany, NJ (D.K., R.M.S., P.L.J.W.).
  • Raal FJ; Department of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (F.J.R.).
Circulation ; 141(22): 1829-1831, 2020 06 02.
Article in En | MEDLINE | ID: mdl-32479195
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Therapy / RNA, Small Interfering / RNA Interference / Molecular Targeted Therapy / PCSK9 Inhibitors / Hyperlipoproteinemia Type II / Cholesterol, LDL Type of study: Clinical_trials Limits: Humans Language: En Journal: Circulation Year: 2020 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Genetic Therapy / RNA, Small Interfering / RNA Interference / Molecular Targeted Therapy / PCSK9 Inhibitors / Hyperlipoproteinemia Type II / Cholesterol, LDL Type of study: Clinical_trials Limits: Humans Language: En Journal: Circulation Year: 2020 Document type: Article Country of publication: United States